Your browser doesn't support javascript.
loading
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
Robson, M E; Tung, N; Conte, P; Im, S-A; Senkus, E; Xu, B; Masuda, N; Delaloge, S; Li, W; Armstrong, A; Wu, W; Goessl, C; Runswick, S; Domchek, S M.
Affiliation
  • Robson ME; Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York. Electronic address: robsonm@mskcc.org.
  • Tung N; Cancer Risk and Prevention Program, Beth Israel Deaconess Medical Center, Department of Medicine, Dana-Farber Harvard Cancer Center, Boston, USA.
  • Conte P; Division of Oncology, University of Padova, Istituto Oncologico Veneto IRCCS, Padova, Italy.
  • Im SA; Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
  • Senkus E; Center of Breast Diseases, Medical University of Gdansk, Gdansk, Poland.
  • Xu B; Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China.
  • Masuda N; Department of Surgery, Osaka National Hospital, National Hospital Organization, Osaka, Japan.
  • Delaloge S; Breast Oncology, Institut Gustave Roussy, Villejuif, France.
  • Li W; Department of Emergency, The First Hospital of Jilin University, Changchun, China.
  • Armstrong A; Medical Oncology, Christie Hospital NHS Foundation Trust, Manchester, UK.
  • Wu W; Global Medicines Development, AstraZeneca, Gaithersburg, USA.
  • Goessl C; Global Medicines Development, AstraZeneca, Gaithersburg, USA.
  • Runswick S; Global Medicines Development, AstraZeneca, Macclesfield, UK.
  • Domchek SM; Department of Medicine, Basser Center, University of Pennsylvania, Philadelphia, USA.
Ann Oncol ; 30(4): 558-566, 2019 04 01.
Article in En | MEDLINE | ID: mdl-30689707
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phthalazines / Piperazines / Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Poly(ADP-ribose) Polymerase Inhibitors Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2019 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phthalazines / Piperazines / Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Poly(ADP-ribose) Polymerase Inhibitors Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2019 Type: Article